Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of Alnylam Pharmaceuticals patents

Patents where

Current Assignee

Name

Alnylam Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 8431693 Process for desilylation of oligonucleotides	Patent 8431693 was granted and assigned to Alnylam Pharmaceuticals on April, 2013 by the United States Patent and Trademark Office.		Alnylam Pharmaceuticals	United States Patent and Trademark Office	8431693	April 30, 2013
‌ US Patent 8013136 Oligonucleotides comprising a non-phosphate backbone linkage	Patent 8013136 was granted and assigned to Alnylam Pharmaceuticals on September, 2011 by the United States Patent and Trademark Office.		Alnylam Pharmaceuticals	United States Patent and Trademark Office	8013136	September 6, 2011
‌ US Patent 7723512 Oligonucleotides comprising a non-phosphate backbone linkage	Patent 7723512 was granted and assigned to Alnylam Pharmaceuticals on May, 2010 by the United States Patent and Trademark Office.		Alnylam Pharmaceuticals	United States Patent and Trademark Office	7723512	May 25, 2010
‌ US Patent 7615618 Oligonucleotides comprising a non-phosphate backbone linkage	Patent 7615618 was granted and assigned to Alnylam Pharmaceuticals on November, 2009 by the United States Patent and Trademark Office.		Alnylam Pharmaceuticals	United States Patent and Trademark Office	7615618	November 10, 2009
‌ US Patent 7632932 Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase	Patent 7632932 was granted and assigned to Alnylam Pharmaceuticals on December, 2009 by the United States Patent and Trademark Office.		Alnylam Pharmaceuticals	United States Patent and Trademark Office	7632932	December 15, 2009
‌ US Patent 7893224 Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase	Patent 7893224 was granted and assigned to Alnylam Pharmaceuticals on February, 2011 by the United States Patent and Trademark Office.		Alnylam Pharmaceuticals	United States Patent and Trademark Office	7893224	February 22, 2011
‌ US Patent 10233448 Modified double-stranded RNA agents	Patent 10233448 was granted and assigned to Alnylam Pharmaceuticals on March, 2019 by the United States Patent and Trademark Office.	Alnylam Pharmaceuticals	Alnylam Pharmaceuticals	United States Patent and Trademark Office	10233448	March 19, 2019
‌ US Patent 7579451 Oligonucleotides comprising a modified or non-natural nucleobase	Patent 7579451 was granted and assigned to Alnylam Pharmaceuticals on August, 2009 by the United States Patent and Trademark Office.		Alnylam Pharmaceuticals	United States Patent and Trademark Office	7579451	August 25, 2009
‌ US Patent 7772387 Oligonucleotides comprising a modified or non-natural nucleobase	Patent 7772387 was granted and assigned to Alnylam Pharmaceuticals on August, 2010 by the United States Patent and Trademark Office.		Alnylam Pharmaceuticals	United States Patent and Trademark Office	7772387	August 10, 2010
‌ US Patent 7674778 Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine	Patent 7674778 was granted and assigned to Alnylam Pharmaceuticals on March, 2010 by the United States Patent and Trademark Office.		Alnylam Pharmaceuticals	United States Patent and Trademark Office	7674778	March 9, 2010
‌ US Patent 7723509 IRNA agents with biocleavable tethers	Patent 7723509 was granted and assigned to Alnylam Pharmaceuticals on May, 2010 by the United States Patent and Trademark Office.		Alnylam Pharmaceuticals	United States Patent and Trademark Office	7723509	May 25, 2010
‌ US Patent 11679158 Biodegradable lipids for the delivery of active agents	Patent 11679158 was granted and assigned to Alnylam Pharmaceuticals on June, 2023 by the United States Patent and Trademark Office.	Alnylam Pharmaceuticals	Alnylam Pharmaceuticals	United States Patent and Trademark Office	11679158	June 20, 2023
‌ US Patent 7829693 Compositions and methods for inhibiting expression of a target gene	Patent 7829693 was granted and assigned to Alnylam Pharmaceuticals on November, 2010 by the United States Patent and Trademark Office.		Alnylam Pharmaceuticals	United States Patent and Trademark Office	7829693	November 9, 2010
‌ US Patent 9012498 Biodegradable lipids for the delivery of active agents	Patent 9012498 was granted and assigned to Alnylam Pharmaceuticals on April, 2015 by the United States Patent and Trademark Office.		Alnylam Pharmaceuticals	United States Patent and Trademark Office	9012498	April 21, 2015
‌ US Patent 9796974 Modified RNAi agents	Patent 9796974 was granted and assigned to Alnylam Pharmaceuticals on October, 2017 by the United States Patent and Trademark Office.	Alnylam Pharmaceuticals	Alnylam Pharmaceuticals	United States Patent and Trademark Office	9796974	October 24, 2017
‌ US Patent 11504391 Modified RNA agents with reduced off-target effect	Patent 11504391 was granted and assigned to Alnylam Pharmaceuticals on November, 2022 by the United States Patent and Trademark Office.	Alnylam Pharmaceuticals	Alnylam Pharmaceuticals	United States Patent and Trademark Office	11504391	November 22, 2022
‌ US Patent 8158601 Lipid formulation	Patent 8158601 was granted and assigned to Alnylam Pharmaceuticals on April, 2012 by the United States Patent and Trademark Office.		Alnylam Pharmaceuticals	United States Patent and Trademark Office	8158601	April 17, 2012
‌ US Patent 11549109 Modified double-stranded RNA agents	Patent 11549109 was granted and assigned to Alnylam Pharmaceuticals on January, 2023 by the United States Patent and Trademark Office.	Alnylam Pharmaceuticals	Alnylam Pharmaceuticals	United States Patent and Trademark Office	11549109	January 10, 2023
‌ US Patent 11427822 Modified double-stranded RNA agents		Alnylam Pharmaceuticals	Alnylam Pharmaceuticals	United States Patent and Trademark Office	11427822	August 30, 2022
‌ US Patent 11401517 Modified double-stranded RNA agents	Patent 11401517 was granted and assigned to Alnylam Pharmaceuticals on August, 2022 by the United States Patent and Trademark Office.	Alnylam Pharmaceuticals	Alnylam Pharmaceuticals	United States Patent and Trademark Office	11401517	August 2, 2022
‌ US Patent 10370666 Ketohexokinase (KHK) iRNA compositions and methods of use thereof	Patent 10370666 was granted and assigned to Alnylam Pharmaceuticals on August, 2019 by the United States Patent and Trademark Office.	Alnylam Pharmaceuticals	Alnylam Pharmaceuticals	United States Patent and Trademark Office	10370666	August 6, 2019
‌ US Patent 11136582 Ketohexokinase (KHK) iRNA compositions and methods of use thereof	Patent 11136582 was granted and assigned to Alnylam Pharmaceuticals on October, 2021 by the United States Patent and Trademark Office.	Alnylam Pharmaceuticals	Alnylam Pharmaceuticals	United States Patent and Trademark Office	11136582	October 5, 2021
‌ US Patent 10369226 Biodegradable lipids for the delivery of active agents	Patent 10369226 was granted and assigned to Alnylam Pharmaceuticals on August, 2019 by the United States Patent and Trademark Office.	Alnylam Pharmaceuticals	Alnylam Pharmaceuticals	United States Patent and Trademark Office	10369226	August 6, 2019
‌ US Patent 8426377 iRNA agents with biocleavable tethers	Patent 8426377 was granted and assigned to Alnylam Pharmaceuticals on April, 2013 by the United States Patent and Trademark Office.		Alnylam Pharmaceuticals	United States Patent and Trademark Office	8426377	April 23, 2013
‌ US Patent 8106022 Carbohydrate conjugates as delivery agents for oligonucleotides	Patent 8106022 was granted and assigned to Alnylam Pharmaceuticals on January, 2012 by the United States Patent and Trademark Office.		Alnylam Pharmaceuticals	United States Patent and Trademark Office	8106022	January 31, 2012

...

Results per page:

366 results

0 selected

366 results

0 selected